Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer
Ayca Gucalp, Joseph A. Sparano, James Caravelli, Jean Santamauro, Sujata Patil, Alyson Abbruzzi, Christine Pellegrino, Jackie Bromberg, Chau Dang, Maria Theodoulou, Joan Massague, Larry Norton, Clifford Hudis, Tiffany A. Traina
Dive into the research topics of 'Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer'. Together they form a unique fingerprint.